Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207115 · ClinicalTrials.gov registry record · Phase 2
A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 322
- Enrollment target
NCT01207115: Completed Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01207115 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 322 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (142% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01207115, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 322 participants
- Enrollment target
Study Summary
To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.
Primary Outcome
Subject reported pain intensity measured by Visual Analog Scale (0-100)
Interventions
- DRUG Placebo
- DRUG Naproxen
- DRUG ABT-652
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
What the finished NCT01207115 record still lists
NCT01207115 is an interventional study that assigns participants to a tested intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (142% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01207115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01207115 about?
NCT01207115 is a clinical study titled "A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee". To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.
What is the current status of trial NCT01207115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 322 participants. The study started on 2010-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01207115?
The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), ABT-652 (DRUG).
Who is sponsoring clinical trial NCT01207115?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01207115's enrollment target sits among peer trials
322 150th of 2000 higher than 1,850 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia